Survey of Maribavir tablets for treating Cytomegalovirus infection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study surveys the use of Maribavir tablets in Japanese participants suffering from Cytomegalovirus (CMV) infection that is resistant to existing anti-CMV therapies, particularly in the context of organ transplantation. Participants will take Maribavir according to their clinic's standard practices, and the study will monitor any side effects over a period of 27 weeks. The study aims to evaluate the effectiveness of Maribavir in protecting against CMV infection and to gather data on its safety profile.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- All participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).

Exclusion Criteria:

\- None

Where it's running

• Takeda selected site
  Tokyo, Tokyo, Japan Recruiting

Study contacts

• Study coordinator: Takeda Contact
• Email: medinfoUS@takeda.com
• Phone: +1-877-825-3327

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Maribavir for CMV in people with lymphoma or multiple myeloma receiving bispecific antibodies

  This will test whether the oral antiviral maribavir can treat CMV reactivation in adults with lymphoma or multiple myeloma who are receiving bispecific antibody therapy.

  Recruiting Phase 2 Seoul National University Hospital · Seoul · NCT07014319

• Preventing CMV after receiving a CMV-positive donor kidney using daily antiviral pills or weekly blood monitoring

  This study will test whether taking daily antiviral pills for 200 days or doing weekly blood checks and treating only if the virus appears is better at preventing CMV disease in adults who get a kidney from a CMV-positive donor and are themselves CMV-negative.

  Recruiting at 6 sites Phase 3 University of California, San Francisco · San Francisco, California and 7 other locations · NCT06798909

• Comparing tests for diagnosing cytomegalovirus in patients with inflammatory bowel disease

  This study is testing different ways to diagnose cytomegalovirus in adults with inflammatory bowel disease who are having worse symptoms and need to be hospitalized.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, Bologna · NCT06793124

• Evaluating LIVTENCITY for treating CMV infection in transplant patients in South Korea

  This study is testing if LIVTENCITY can safely and effectively treat cytomegalovirus (CMV) infection in adults who have had a transplant and haven't had success with other treatments.

  Recruiting Takeda · Seoul · NCT06555432

• Maribavir for CMV in adults with kidney failure after transplantation

  This project will see if maribavir is safe for adults with severe kidney failure (including people on dialysis) who develop CMV after a transplant by reviewing existing medical records.

  Recruiting at 9 sites Takeda · Anderlecht, Brussels Capital and 24 other locations · NCT06243731

• Maribavir treatment for CMV infection in children and adolescents after stem cell or organ transplant

  This study tests whether maribavir is safe and works to treat CMV infection in children and teenagers who have had a stem cell or solid organ transplant.

  Recruiting at 53 sites Phase 3 Takeda · Wilmington, Delaware and 52 other locations · NCT05319353

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.